ADM CEO sheds light on probiotics strategy

ADM CEO sheds light on probiotics strategy

CHICAGO โ€” Success ADM has achieved in becoming a global leader in the probiotic category points to opportunities the company sees in the nutrition space more broadly and as a vehicle to help sustain strong financial performance well into the future, said Juan R. Luciano.

In a dialogue with Alexia J.B. Howard, a senior analyst with Sanford C. Bernstein & Co., LLC, Mr. Luciano spoke expansively about ADMโ€™s high level strategic objectives. At the same time, he became more granular in discussing ADMโ€™s emerging Nutrition business.

The May 31 discussion was part of the Sanford C. Bernstein Strategic Decisions Conference.

Mr. Luciano projected the Nutrition division would reach $1 billion in operating profits โ€œvery soon,โ€ compared with $736 million in 2022 and $691 million in 2021. ADMโ€™s total adjusted operating profits in 2022 were $6.6 billion.

He said ADM became โ€œexcited about the microbiomeโ€ in the mid-2010s, setting in motion from modest beginnings a series of investments in the space. Six years later, ADM has the top selling branded bioactive supplement on Amazon, Mr. Luciano said.

โ€œWe believe strongly in the connection between food and the microbiome,โ€ he said. โ€œWe acquired first a company for less than โ‚ฌ20 million.โ€

ADM in March 2017 acquired a 90% stake in Biopolis S.L. a biotechnology company engaged in research, development and production services with broad applications โ€” including food, pharmaceuticals, chemicals and energy. Powering this capability, Biopolis said, was a โ€œa multidisciplinary team of highly qualified personnel with proven experience in the fields of biochemistry, molecular biology, fermentative process scaling, genetics, chemical engineering, microbiology, nutrition and food technology.โ€

โ€œWe acquired basically 65 PhDs,โ€ Mr. Luciano said. โ€œOf course, then we didnโ€™t have a lot of capacity. We didnโ€™t have a lot of ability to sell.โ€

About 17 months later, ADM gained capacity with the August 2018 acquisition of Probiotics International Ltd. for ยฃ185 million. Known more commonly under its brand name Protexin, the company is a UK-based manufacturer of health care and probiotic supplements for human, pet and production-animal use.

โ€œ(Protexin) was a marketing machineโ€ able to bring to market the technology developed and clinical trials conducted by Biopolis, Mr. Luciano said.

In November 2021 ADM acquired capacity in the United States with the acquisition of Deerland Probiotics & Enzymes, a supplier of dietary supplements using probiotic, prebiotic and enzyme technology.

โ€œToday, ADM has the No. 1 bioactive selling brand in Amazon,โ€ Mr. Luciano said. โ€œBio-Kult is one of those brands. So is Protexin. You donโ€™t relate ADM to having the No. 1 brand on Amazon selling bioactives, but we do have that.โ€

For ADM, probiotics (only one example of what is produced by these businesses) offers synergies for ADM since the markets are large both for humans and for animals, Mr. Luciano said. He said the growth potential is extraordinary, noting that on the human side, vitamins and supplements have US household penetration of 80% to 90%. He noted that this penetration has been sustained even though doctors frequently tell patients supplements may not be helpful.

โ€œIn probiotics that are 100% certified with clinical trials,โ€ he said. โ€œThe penetration in homes is about 10% to 15%. So the headspace that people become more familiar with that is spectacular.โ€

ADM is devoting considerable resources to tap into this potential, he said. He cited a recently inaugurated $30 million production facility in Valencia, home of Biopolis, as an example of the companyโ€™s commitment to the category.

โ€œI never expanded like this,โ€ he said. โ€œI have 35 years in business. We expanded capacity by a factor of five. I never expanded capacity by a factor of five on anything in my life, but thatโ€™s how much growth weโ€™re having.โ€

More broadly, Mr. Luciano said ADMโ€™s Nutrition business is โ€œhalfway (toward) being built.โ€

โ€œWe need to continue to do that,โ€ he said. โ€œThere is huge opportunity in health and wellness and all what I mentioned before about microbiome. We are a very successful human nutrition company, but only in North America and Europe. Weโ€™re still very underrepresented in the developing world.โ€